Article Sidebar
Published:
Mar 18, 2019Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Thyroid function in chronic hepatitis C patients treated with interferon
Abstract
Purpose: To investigate the effect of interferon (IFN) treatment for chronic hepatitis C (CHC) patients on thyroid function.
Methods: 65 patients (27 males and 38 females, aged 28 - 61 years) with mild or moderate CHC and early fibrosis admitted to Second Hospital of Lanzhou University from January 2017 to January 2018 were enrolled in this study, while 65 healthy subjects served as the control group. The study group received 135μg peginterferon alfa-2a injection (Peloxin) subcutaneously, once a week for 48 weeks. Ribavirin was administered orally once a day at doses ranging from 10 - 15 mg/kg body weight. Chemiluminescence immunoassay was used to measure thyroid hormone and antibody levels in both groups.
Results: After interferon therapy, the positive expressions of TGAb and TPOAb in the study group were lower than the corresponding values observed before treatment (χ2 = 8.188, p = 0.004; χ2 = 11.527, p < 0.001). Thyroid hormone levels in the study group were normal before treatment, but free triiodothyronine (FT3) and free thyroxine (FT4) were significantly lower in the study group (t1 = -9.58, t2 = -14.61, p < 0.001). However, FT3 and FT4 significantly increased after treatment in the study group, relative to the control group (p < 0.05). The level of TSH in the study group was significantly higher than the level before treatment (p < 0.05), but gradually returned to normal.
Conclusion: Chronic hepatitis C patients may have thyroid dysfunction, and IFN therapy may result in transient disorder in thyroid hormone metabolism. Thus, TSH, TGAb and TPOAb can be used as predictors of thyroid disease development during IFN therapy for CHC.
Keywords: Chronic hepatitis C, Thyroid hormone, Anti-thyroid autoantibody, Interferon
